

## Generics Market Summary, Competitive Analysis and Forecast to 2027

Industry Report | 2023-08-17 | 297 pages | MarketLine

## **AVAILABLE LICENSES:**

- Single user licence (PDF) \$1495.00
- Site License (PDF) \$2990.00
- Enterprisewide license (PDF) \$4485.00

## **Report description:**

Generics Market Summary, Competitive Analysis and Forecast to 2027

### Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

### Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.

- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

Regional volumes are calculated as weighted averages of countries that comprise the region where volume data exists.
 All market data and forecasts are represented in nominal terms (i.e., without adjustment for inflation) and all currency conversions used in the creation of this report have been calculated using constant 2022 annual average exchange rates.
 The global generics market had total revenues of \$336.9 billion in 2022, representing a compound annual growth rate (CAGR) of

7.2% between 2017 and 2022.

Market consumption volume increased with a CAGR of 1.8% between 2017 and 2022, to reach a total of 40.1% in 2022.
In 2022, the growth of the global generics market decelerated, witnessing an annual growth of 7.2% due to the reduction in generic drug prices.

#### Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the global generics market by value in 2022?
- What will be the size of the global generics market in 2027?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?

## **Table of Contents:**

Table of Contents

- **1 EXECUTIVE SUMMARY**
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Competitive landscape
- 2 Introduction
- 2.1. What is this report about?
- 2.2. Who is the target reader?
- 2.3. How to use this report
- 2.4. Definitions
- 3 Global Generics
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in Asia-Pacific
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Generics in Europe
- 6.1. Market Overview

6.2. Market Data 6.3. Market Segmentation 6.4. Market outlook 6.5. Five forces analysis 7 Macroeconomic Indicators 7.1. Country data 8 Generics in France 8.1. Market Overview 8.2. Market Data 8.3. Market Segmentation 8.4. Market outlook 8.5. Five forces analysis 9 Macroeconomic Indicators 9.1. Country data 10 Generics in Germany 10.1. Market Overview 10.2. Market Data 10.3. Market Segmentation 10.4. Market outlook 10.5. Five forces analysis 11 Macroeconomic Indicators 11.1. Country data 12 Generics in Italy 12.1. Market Overview 12.2. Market Data 12.3. Market Segmentation 12.4. Market outlook 12.5. Five forces analysis 13 Macroeconomic Indicators 13.1. Country data 14 Generics in Japan 14.1. Market Overview 14.2. Market Data 14.3. Market Segmentation 14.4. Market outlook 14.5. Five forces analysis 15 Macroeconomic Indicators 15.1. Country data 16 Generics in Australia 16.1. Market Overview 16.2. Market Data 16.3. Market Segmentation 16.4. Market outlook 16.5. Five forces analysis 17 Macroeconomic Indicators 17.1. Country data 18 Generics in Canada

18.1. Market Overview 18.2. Market Data 18.3. Market Segmentation 18.4. Market outlook 18.5. Five forces analysis **19** Macroeconomic Indicators 19.1. Country data 20 Generics in China 20.1. Market Overview 20.2. Market Data 20.3. Market Segmentation 20.4. Market outlook 20.5. Five forces analysis 21 Macroeconomic Indicators 21.1. Country data 22 Generics in The Netherlands 22.1. Market Overview 22.2. Market Data 22.3. Market Segmentation 22.4. Market outlook 22.5. Five forces analysis 23 Macroeconomic Indicators 23.1. Country data 24 Generics in Spain 24.1. Market Overview 24.2. Market Data 24.3. Market Segmentation 24.4. Market outlook 24.5. Five forces analysis 25 Macroeconomic Indicators 25.1. Country data 26 Generics in The United Kingdom 26.1. Market Overview 26.2. Market Data 26.3. Market Segmentation 26.4. Market outlook 26.5. Five forces analysis 27 Macroeconomic Indicators 27.1. Country data 28 Generics in The United States 28.1. Market Overview 28.2. Market Data 28.3. Market Segmentation 28.4. Market outlook 28.5. Five forces analysis 29 Macroeconomic Indicators 29.1. Country data

30 Company Profiles

- 30.1. Teva Pharmaceutical Industries Limited
- 30.2. Pfizer Inc.
- 30.3. Sun Pharmaceutical Industries Ltd
- 30.4. Viatris Inc.
- 30.5. Sanofi SA
- 30.6. Les Laboratoires Servier
- 30.7. STADA Arzneimittel AG
- 30.8. Novartis AG
- 30.9. Daiichi Sankyo Co Ltd
- 30.10. Sawai Pharmaceutical Co Ltd
- 30.11. Lupin Ltd
- 30.12. Aspen Pharmacare Holdings Ltd
- 30.13. Apotex, Inc.
- 30.14. Grand Pharmaceutical Group Limited
- 30.15. Esteve Group
- 31 Appendix
- 31.1. Methodology
- 31.2. About MarketLine



# Generics Market Summary, Competitive Analysis and Forecast to 2027

Industry Report | 2023-08-17 | 297 pages | MarketLine

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

### **ORDER FORM:**

Select license	License		Price
	Single user licence (PDF)		\$1495.00
	Site License (PDF)		\$2990.00
	Enterprisewide license (PDF)		\$4485.00
		VAT	
		Total	

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-06
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com